EUROPEAN MARKETS FOR SKIN REPLACEMENTS/SUBSTITUTES AND ACTIVE WOUND REPAIR MODULATORS

168 Pages | 29 Exhibits | 2010 Analysis | Forecasts Through 2013 Product Family: Market Reports




OVERVIEW:
Over the past two decades, dramatic advances have been made in the management of wound patients. These factors have greatly improved the ability of clinicians to overcome many of the previously irresolvable issues associated with the treatment of acute and chronic wounds. In 2009, European sales of skin replacements and substitutes and active wound repair modulators totaled approximately $391 million, with skin replacements and substitutes accounting for 48% of sales and active wound repair modulators accounting for the remaining 52% of sales. Over the forecast period covered by this report, total sales are expected to increase at a compound annual rate of 9.2%, reaching approximately $557 in the year 2013.

This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European skin replacements and substitutes and active wound repair modulators market. Major topics covered by this report include an overview of the healthcare markets of France, Germany, Italy, Spain, and the United Kingdom; an overview of clinical issues in wound management; skin replacement and substitutes including allografts, autografts, xenografts, amniotic membranes, and autologous and tissue-engineered skin replacements and substitutes (e.g., epidermal, dermal, and composite bilayer skin equivalents); and active wound repair modulators including topical antimicrobials, growth factors, gene therapy agents, antibiotics/anti-infectives, hormones, matrix metalloproteinase enzyme inhibitors, neuropeptides, and stem cells.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Clinical Issues in Wound Management
ii. Skin Replacements and Substitutes
	a. Allografts
	b. Autografts
	c. Xenografts
	d. Amniotic Membranes
	e. Skin Equivalents
	f. Skin Replacements and Substitutes, Market Analysis
iii. Active Wound Repair Modulators
	a. Topical Antimicrobial Products
	b. Growth Factors
	c. Other Active Wound Repair Modulators
	d. Active Wound Repair Modulators, Market Analysis
iv. Combined Market Analysis
	a. Market Drivers
	b. Market Limiters
	c. Combined Market Forecast

Exhibit ES-1: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013
Exhibit ES-2: Europe, Active Wound Repair Modulators, Market Forecast, by Country, 2008-2013
Exhibit ES-3: Europe, Skin Replacements and Substitutes and Active Wound Repair Modulators, Combined Market Forecast, by Country, 2008-2013

1. EUROPEAN HEALTHCARE MARKETS

1.1 The European Union
	1.1.1 A Common Currency
	1.1.2 Regulatory Policies
	1.1.3 Reimbursement
	1.1.4 Healthcare Spending
1.2 Selected European National Healthcare Profiles
	1.2.1 France
		1.2.1.1 Healthcare Organization and Reform
		1.2.1.2 Hospital Services
		1.2.1.3 Medical Device Reimbursement
	1.2.2 Germany
		1.2.2.1 Healthcare Organization and Reform
		1.2.2.2 Hospital Services
		1.2.2.3 Medical Device Reimbursement
	1.2.3 Italy
		1.2.3.1 Healthcare Organization and Reform
		1.2.3.2 Hospital Services
		1.2.3.3 Medical Device Reimbursement
	1.2.4 Spain
		1.2.4.1 Healthcare Organization and Reform
		1.2.4.2 Hospital Services
		1.2.4.3 Medical Device Reimbursement
	1.2.5 United Kingdom
		1.2.5.1 Healthcare Organization and Reform
		1.2.5.2 Hospital Services
		1.2.5.3 Medical Device Reimbursement

Exhibit 1-1: European Union, Medical Devices Risk Classification System
Exhibit 1-2: European Union Population Statistics Comparison for the Years 1999, 2009, and 2019
Exhibit 1-3: France, Selected National Healthcare Statistics
Exhibit 1-4: Germany, Selected National Healthcare Statistics
Exhibit 1-5: Italy, Selected National Healthcare Statistics
Exhibit 1-6: Spain, Selected National Healthcare Statistics
Exhibit 1-7: United Kingdom, Selected National Healthcare Statistics

2. CLINICAL ISSUES IN WOUND MANAGEMENT

2.1 Physiology of Wound Closure
	2.1.1 Layers of the Skin and Supporting Structures
		2.1.1.1 Epidermis
		2.1.1.2 Dermis
		2.1.1.3 Subcutaneous Tissue
		2.1.1.4 Fascia
		2.1.1.5 Muscle
		2.1.1.6 Bone
	2.1.2 Wound Closure Process
		2.1.2.1 Hemostasis
		2.1.2.2 Inflammation
		2.1.2.3 Proliferation
		2.1.2.4 Remodeling Phase
2.2 Factors Affecting Wound Closure
	2.2.1 Extrinsic Factors
		2.2.1.1 Desiccation
		2.2.1.2 Hydration
		2.2.1.3 Infection
		2.2.1.4 Maceration
		2.2.1.5 Medication and Other Treatment Modalities
		2.2.1.6 Necrotic Tissue and Debris
		2.2.1.7 Oxygenation
		2.2.1.8 Stress
		2.2.1.9 Temperature
		2.2.1.10 Wound Creation and Depth
		2.2.1.11 Wound Closure Techniques
		2.2.1.12 Other Extrinsic Factors
	2.2.2 Intrinsic Factors
		2.2.2.1 Body Build
		2.2.2.2 Chronic Illness and Age
		2.2.2.3 Nutrition
	2.2.3 Complications of Wound Healing
		2.2.3.1 Bleeding
		2.2.3.2 Scarring
2.3 Major Wound Types
	2.3.1 Amputation
	2.3.2 Arterial Ulcers
	2.3.3 Burns
	2.3.4 Diabetic Ulcers
	2.3.5 Pressure Ulcers
	2.3.6 Surgical Wounds
	2.3.7 Traumatic Wounds
	2.3.8 Venous Ulcers

Exhibit 2-1: The Skin's Layers and Supporting Structures
Exhibit 2-2: Phases of the Wound Closure Process
Exhibit 2-3: Extrinsic and Intrinsic Factors Affecting Wound Closure
Exhibit 2-4: Major Wound Types, by Cause
Exhibit 2-5: Stages of Burn Wounds
Exhibit 2-6: Stages of Pressure Ulcers
Exhibit 2-7: 2008, Europe, Surgical Procedure Volumes, by Type

3. SKIN REPLACEMENTS AND SUBSTITUTES MARKET

3.1 Allografts
3.2 Autografts
3.3 Xenografts
3.4 Amniotic Membranes
3.5 Autologous and Tissue-Engineered Skin Replacements and Substitutes
	3.5.1 Epidermal Equivalents
	3.5.2 Dermal Equivalents
	3.5.3 Composite Bilayer Skin Equivalents
3.6 Skin Substitute Products under Development
	3.6.1 Advanced BioHealing
	3.6.2 Healthpoint/DFB Pharmaceuticals
	3.6.3 Organogenesis
	3.6.4 Dr. Suwelack Skin & Health Care
3.7 Market Analysis
3.8 Competitive Analysis

Exhibit 3-1: Advantages and Disadvantages of Allografts
Exhibit 3-2: 2010, Selected Epidermal Equivalent Skin Substitutes
Exhibit 3-3: 2010, Selected Dermal Equivalent Skin Substitutes
Exhibit 3-4: 2010, Selected Composite Bilayer Equivalent Skin Substitutes
Exhibit 3-5: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013
Exhibit 3-6: 2009, Europe, Skin Replacements and Substitutes Market, Share by Supplier

4. ACTIVE WOUND REPAIR MODULATORS MARKET

4.1 Topical Antimicrobials
	4.1.1 Products
	4.1.2 Market Analysis
	4.1.3 Competitive Analysis
4.2 Growth Factors
	4.2.1 Classification of Growth Factors
		4.2.1.1 Fibroblast Growth Factors
		4.2.1.2 Transforming Growth Factors
		4.2.1.3 Epidermal Growth Factors
		4.2.1.4 Platelet-Derived Growth Factors
		4.2.1.5 Insulin-Like Growth Factors
		4.2.1.6 Keratinocyte Growth Factors
		4.2.1.7 Vascular Endothelial Growth Factors
		4.2.1.8 Autologous Growth Factors
			4.2.1.8.1 Arteriocyte Medical Systems
			4.2.1.8.2 Cytomedix
			4.2.1.8.3 Harvest Technologies
		4.2.1.9 Angiogenic Growth Factors
	4.2.2 Products
	4.2.3 Market Analysis
4.3 Gene Therapy Agents
4.4 Other Active Wound Repair Modulators
	4.4.1 Antibiotics and Anti-Infectives
		4.4.1.1 Basilea Pharmaceutica
		4.4.1.2 Cerexa/Forest Laboratories
		4.4.1.3 Cubist Pharmaceuticals
		4.4.1.4 Helix BioMedix
		4.4.1.5 Theravance
	4.4.2 Hormones
	4.4.3 Matrix Metalloproteinase Enzyme Inhibitors
		4.4.3.1 Dermagenics/Greystone Pharmaceuticals
		4.4.3.2 Smith & Nephew
		4.4.3.3 Systagenix Wound Management
	4.4.4 Neuropeptides in Diabetic Wounds
	4.4.5 Stem Cells
	4.4.6 Other Products
		4.4.6.1 Kingfisher Healthcare
		4.4.6.2 Pioneer Surgical Orthobiologics/Pioneer Surgical Technology
		4.4.6.3 RegeneRx Biopharmaceuticals

Exhibit 4-1: 2010, Selected Topical Antimicrobial Products
Exhibit 4-2: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2008-2013
Exhibit 4-3: 2009, Europe, Topical Antimicrobial Products, Share by Supplier
Exhibit 4-4: 2010, Selected Growth Factors in Development for Wound Healing Applications
Exhibit 4-5: 2010, Selected Angiogenic Growth Factors
Exhibit 4-6: Europe, Growth Factors Used in Wound Healing Applications, Market Forecast,  by Country, 2008-2013

5. COMPANY PROFILES

5.1 Advanced BioHealing, Inc.
5.2 Cook Biotech, Inc./Cook Group, Inc.
5.3 Cytomedix, Inc.
5.4 Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc.
5.5 GlaxoSmithKline PLC
5.6 Integra LifeSciences Corporation
5.7 LEO Pharma AS/LEO Foundation
5.8 sanofi-aventis
5.9 Smith & Nephew PLC
5.10 Systagenix Wound Management LTD

APPENDIX: COMPANY LISTING


COMPANIES COVERED:

  1. Advanced BioHealing, Inc.
  2. Cook Biotech, Inc./Cook Group, Inc.
  3. Cytomedix, Inc.
  4. Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc.
  5. GlaxoSmithKline PLC
  6. Integra LifeSciences Corporation
  7. LEO Pharma AS/LEO Foundation
  8. sanofi-aventis
  9. Smith & Nephew PLC
  10. Systagenix Wound Management LTD
Contact Us

Need help finding medtech research? Let us help you!